Ipsen Bioscience Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$49.0M
Doctors Paid
152
Transactions
4,364
2024 Total
$3.8M
Payment Breakdown by Category
Research$34.1M (69.4%)
Royalty/License$13.4M (27.2%)
Consulting$1.5M (3.1%)
Travel$55,093 (0.1%)
Food & Beverage$18,875 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $34.1M | 3,908 | 69.4% |
| Royalty or License | $13.4M | 14 | 27.2% |
| Consulting Fee | $1.5M | 182 | 3.1% |
| Travel and Lodging | $55,093 | 132 | 0.1% |
| Food and Beverage | $18,875 | 122 | 0.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,945 | 3 | 0.0% |
| Honoraria | $10,004 | 3 | 0.0% |
Payments by Type
Research
$34.1M
3,908 transactions
General
$15.0M
456 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas | $8.5M | 0 | 1,256 |
| A Phase I, Single-Centre, Open-Label, Repeat Dose Study to Assess the Pharmacokinetics, Safety and Tolerability Following Administration of Elafibranor in Healthy Japanese and Non-Asian Participants | $2.6M | 0 | 25 |
| RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy | $2.4M | 1 | 330 |
| PK Japan | $2.3M | 0 | 51 |
| An Open-label Randomised Multicentre Phase III Study of Irinotecan Liposome Injection Oxaliplatin 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas | $1.6M | 0 | 140 |
| A Phase 2 Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Paediatric and Adult Participants. | $1.5M | 0 | 69 |
| A Phase I Study in Patients Treated With MM-398 Nanoliposomal Irinotecan, Nal-IRI to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment | $1.4M | 0 | 64 |
| A Phase 2, Two-part, Placebo-controlled, Parallel-group, Double-blind Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral IPN60130 for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Participants 5 Years of Age and Older. | $1.3M | 7 | 181 |
| A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | $1.1M | 4 | 342 |
| A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan Nal-IRI-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma | $1.1M | 0 | 525 |
| An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracilLeucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas | $995,814 | 1 | 72 |
| A Phase I, Open Label, Dose Escalation and Dose Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumour Activity of IPN60090 as Single Agent and in Combination in Patients With Advanced Solid Tumours | $897,009 | 0 | 9 |
| A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | $831,046 | 5 | 313 |
| RESILIENT A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection ONIVYDE Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy | $707,651 | 1 | 340 |
| A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | $223,066 | 0 | 71 |
| A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma | $167,114 | 0 | 22 |
| Ellucidating the Role of Cytokness in Patients with Pancreatic Cancer | $116,508 | 0 | 1 |
| NCT04083235 | $107,143 | 0 | 50 |
| Ipsen Harvard Catalyst | $100,000 | 0 | 1 |
| A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for the Treatment of Pain Associated With Hallux Abducto Valgus | $80,494 | 0 | 18 |
| Validation of the modified Foot Function Index mFFI for Use in Hallux Valgus | $8,800 | 0 | 2 |
| A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) | $2,656 | 0 | 1 |
| MM-398-07-02-03 | $2,500 | 0 | 1 |
| An Efficacy and Safety Study of Somatuline Depot Lanreotide Injection to Treat Carcinoid Syndrome ELECT | $1,495 | 0 | 1 |
| A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot Lanreotide Injection in the Treatment of Carcinoid Syndrome | $640.00 | 0 | 2 |
| A Phase III, Multicentre, Prospective, Open Label Extension Study to Assess the Long Term Safety and Efficacy of Repeated Treatment of Dysport Intramuscular Injections Used for the Treatment of Upper Limb Spasticity in Adult Subjects With Spastic Hemiparesis Due to Stroke or Traumatic Brain Injury | $630.00 | 0 | 2 |
| ARandomized, Open-label Phase 2 Study of Nanoliposomal IrinotecanNal-IRI-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma | $256.22 | 0 | 6 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Peter Kowey, Md, MD | Clinical Cardiac Electrophysiology | Wynnewood, PA | $7,200 | $0 |
| Dr. Erik Mittra, M.d., Ph.d, M.D., PH.D | Nuclear Medicine | Portland, OR | $7,200 | $0 |
| Edmund Kopetz, M.d, M.D | Medical Oncology | Houston, TX | $6,873 | $0 |
| Mr. Babak Baravarian, Dpm, DPM | Podiatrist | Santa Monica, CA | $6,802 | $0 |
| Dr. Jasgit Sachdev, M.d, M.D | Student in an Organized Health Care Education/Training Program | Tempe, AZ | $6,793 | $0 |
| Alberto Esquenazi, Md, MD | Physical Medicine & Rehabilitation | Philadelphia, PA | $6,742 | $0 |
| Nuhad Ibrahim, M.d, M.D | Medical Oncology | Houston, TX | $6,640 | $0 |
| Dr. David Robbins, M.d, M.D | Specialist | Kansas City, KS | $6,555 | $0 |
| Jodi Segal, Md, MD | Internal Medicine | Baltimore, MD | $6,270 | $0 |
| Nelson Watts, M.d, M.D | Internal Medicine | Cincinnati, OH | $6,270 | $0 |
| William Tap, Md, MD | Hematology & Oncology | New York, NY | $6,090 | $0 |
| Dr. Peter Kaufman, Md, MD | Hematology | Lebanon, NH | $5,857 | $0 |
| Dr. William Nibley, M.d, M.D | Hematology & Oncology | Murray, UT | $5,590 | $0 |
| Dr. Brendan Everett, Md, Mph, MD, MPH | Internal Medicine | Boston, MA | $5,415 | $0 |
| James Yao, M.d, M.D | Medical Oncology | Houston, TX | $5,400 | $0 |
| Daniel Halperin, Md, MD | Medical Oncology | Houston, TX | $5,220 | $0 |
| Dr. Marcelo Kugelmas, M.d, M.D | Gastroenterology | Englewood, CO | $5,044 | $0 |
| Paul Thuluvath, M.d, M.D | Gastroenterology | Baltimore, MD | $4,924 | $0 |
| Norman Latov, Md, MD | Neurology | New York, NY | $4,500 | $0 |
| David Cohen, Md Phd, MD PHD | Gastroenterology | Boston, MA | $4,500 | $0 |
| Dr. Angela Ugwuanyi, Dnp, Np-C, DNP, NP-C | Family | Germantown, TN | $4,362 | $0 |
| Helena Yu, Md, MD | Internal Medicine | New York, NY | $4,350 | $0 |
| Mr. Bhaktasharan Patel, Md, MD | Gastroenterology | Colorado Springs, CO | $4,132 | $0 |
| Eric Liu, M.d, M.D | Surgical Oncology | Denver, CO | $4,000 | $0 |
| Eileen O'reilly, Md, MD | Medical Oncology | New York, NY | $3,571 | $0 |
Ad
Top Products
- ONIVYDE $12.9M
- Onivyde $3.7M
Payment Categories
- Food & Beverage $18,875
- Consulting $1.5M
- Travel & Lodging $55,093
- Research $34.1M
- Royalties $13.4M
About Ipsen Bioscience Inc.
Ipsen Bioscience Inc. has made $49.0M in payments to 152 healthcare providers, recorded across 4,364 transactions in the CMS Open Payments database. In 2024, the company paid $3.8M. The top product by payment volume is ONIVYDE ($12.9M).
Payments were distributed across 38 medical specialties. The top specialty by payment amount is Gastroenterology ($600,120 to 16 doctors).
Payment categories include: Food & Beverage ($18,875), Consulting ($1.5M), Research ($34.1M), Travel & Lodging ($55,093), Royalties ($13.4M).